FDA grants approval to Regeneron for Pasatru, a treatment targeting an ultra-rare bone disorder.

REGN · Regeneron Pharmaceuticals, Inc.

The AI's read

Regeneron won FDA approval for Pasatru for FOP, a drug that blocks Activin A and showed ~90%+ elimination of new lesions in Phase 3. That directly de-risks a late-stage program and adds a commercial product to Regeneron's lineup. The market reaction is muted, with REGN down about 0.6% premarket and RSI ~42, not overstretched. The treated population is tiny, roughly 900 diagnosed worldwide, so headline approval does not promise blockbuster scale. Catalyst is real but asymmetric upside looks limited until pricing, reimbursement, and launch data arrive, so we lean neutral. Positioning: acknowledge the win but wait for commercial math and regulatory details before getting more bullish.